ClinicalTrials.Veeva

Menu

The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS)

U

University of Alberta

Status and phase

Completed
Phase 2

Conditions

Amyotrophic Lateral Sclerosis

Treatments

Drug: Memantine

Study type

Interventional

Funder types

Other

Identifiers

NCT00409721
EB2006ALS
1204

Details and patient eligibility

About

The purpose of the study is to investigate the effects of memantine in ALS patients using functional outcome measures.

Enrollment

42 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • El Escorial Classification of laboratory supported probable, probable,or definite ALS
  • Age 18 - 80 years,
  • ALS symptoms for no more than 3 years,
  • FVC greater than or equal to 60% predicted,
  • Riluzole naïve or have been on a stable dose of Riluzole for at least 2 months,
  • Patients must have the ability to attend monthly study visits in Edmonton or Calgary, Alberta

Exclusion criteria

  • Presence of significant sensory abnormalities, dementia, other neurologic diseases, uncompensated medical illness and psychiatric illness
  • Female patients who are breastfeeding
  • Use of concurrent investigational drugs,
  • Patient unlikely to comply with study requirements
  • Poor adherence to study protocol during run-in phase

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

42 participants in 2 patient groups

Memantine Low Dose
Experimental group
Treatment:
Drug: Memantine
Memantine High Dose
Experimental group
Treatment:
Drug: Memantine

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems